Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome.
暂无分享,去创建一个
Kris Chang | D. Bickers | R. Yauch | Jean Y. Tang | M. Aszterbaum | E. Epstein | Jean Y. Tang | Julian M. Mackay-Wiggan | Michelle Aszterbaum | Robert L. Yauch | Joselyn Lindgren | Carol Coppola | Anita M. Chanana | Jackleen Marji | David R. Bickers | Ervin H. Epstein | J. Mackay-Wiggan | Joselyn A. Lindgren | Kris Chang | Anita M. Chanana | J. Marji | J. Lindgren | C. Coppola | J. Tang | Jean Y. Tang | J. Tang | Jean Y. Tang | Julian M. Mackay-Wiggan
[1] M. Grachtchouk,et al. Sustained Hedgehog signaling is required for basal cell carcinoma proliferation and survival: conditional skin tumorigenesis recapitulates the hair growth cycle. , 2005, Genes & development.
[2] P. McCullagh,et al. Generalized Linear Models , 1972, Predictive Analytics.
[3] M. Scott,et al. Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. , 1998, The Journal of investigative dermatology.
[4] Michael Dean,et al. Mutations of the Human Homolog of Drosophila patched in the Nevoid Basal Cell Carcinoma Syndrome , 1996, Cell.
[5] Aleksandar Sekulic,et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. , 2012, The New England journal of medicine.
[6] M. Wolter,et al. Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. , 1998, Cancer research.
[7] R. Gorlin. Nevoid Basal‐Cell Carcinoma Syndrome , 1987, Dermatologic clinics.
[8] Jussi Taipale,et al. Small molecule modulation of Smoothened activity , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[9] C. Rudin,et al. Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma , 2009, Science.
[10] N. Hanna,et al. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2008 .
[11] John A. Nelder,et al. Generalized linear models. 2nd ed. , 1993 .
[12] D. Albertson,et al. Loss of Blm enhances basal cell carcinoma and rhabdomyosarcoma tumorigenesis in Ptch1+/- mice. , 2010, Carcinogenesis.
[13] E. Blackburn. Cancer Interception , 2011, Cancer Prevention Research.
[14] J. Baselga,et al. A phase I dose-escalation study of LDE225, a smoothened (Smo) antagonist, in patients with advanced solid tumors. , 2010 .
[15] Michael Dean,et al. Is human patched the gatekeeper of common skin cancers? , 1996, Nature Genetics.
[16] R. Myers,et al. Human Homolog of patched, a Candidate Gene for the Basal Cell Nevus Syndrome , 1996, Science.
[17] Kristine Rose,et al. Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor. , 2011, The Journal of investigative dermatology.
[18] P. McCullagh,et al. Generalized Linear Models, 2nd Edn. , 1990 .
[19] F. Pontén,et al. PATCHED and p53 gene alterations in sporadic and hereditary basal cell cancer , 2001, Oncogene.
[20] M A Weinstock,et al. Nonmelanoma skin cancer in the United States: incidence. , 1994, Journal of the American Academy of Dermatology.
[21] Hideo Nakamura,et al. Essential role of the Hedgehog signaling pathway in human glioma‐initiating cells , 2011, Cancer science.
[22] A. Goldstein,et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. , 1997, American journal of medical genetics.
[23] Tannishtha Reya,et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia , 2009, Nature.
[24] Q. Gu,et al. Activating Smoothened mutations in sporadic basal-cell carcinoma , 1998, Nature.
[25] Raoul Tibes,et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. , 2009, The New England journal of medicine.
[26] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.
[27] E. Epstein. Basal cell carcinomas: attack of the hedgehog , 2008, Nature Reviews Cancer.